Other Clinical Trial - The HepQuant SHUNT Test for Monitoring Liver

Status Terminated

Clinical Trial Summary

The HepQuant SHUNT test, which is provided as a HepQuant SHUNT Liver Diagnostic Kit, is a minimally-invasive test of liver function and physiology which has been designated by the FDA as an investigational drug/device combination product. Enrollment into one of the 3 Gilead Selonsertib clinical trials (GS-US-416-2124, GS-US-384-1943/1944) is required for enrollment into the HepQuant study

Clinical Trial Description

The HepQuant study is to run parallel to the Gilead clinical trials,GS-US-416-2124 trial of Alcoholic Hepatitis, GS-US-384-1943 trial of non-alcoholic steatohepatitis (NASH) fibrosis Stage 3 (STELLAR-3), and, GS-US-384-1944 trial of NASH and compensated cirrhosis (STELLAR-4). The time points for the HepQuant SHUNT tests coincide with pre-specified time points within the Gilead clinical trials. Subjects enrolled in GILEAD's STELLAR and Alcoholic hepatitis trials may participate concurrently in this HepQuant sponsored investigational device study at participating US sites only (IDEs as listed above) once approved by the applicable IRB/IEC. The main eligibility criteria for enrollment into the HepQuant study is enrollment into one of the three Gilead clinical trials listed above. The HepQuant SHUNT Test is minimally-invasive and measures hepatocyte function and inflow to the liver from the simultaneous clearances (hepatic filtration rates, HFRs) of cholate from systemic and portal circulations. The Test quantifies portal-systemic shunting (SHUNT) and generates a liver disease severity index (DSI). DSI is a score from 0 (no disease) to 50 (terminal illness) that is a composite of both HFRs and correlates with stage of fibrosis, presence of varices, especially large varices, and risk for future clinical outcomes. DSI is the primary output variable from the HepQuant SHUNT test. The HepQuant SHUNT test potentially satisfies the unmet medical need for a minimally-invasive test of global liver function and physiology ;

Study Design

Related Conditions & MeSH terms

Fatty Liver
Liver Diseases
NASH - Nonalcoholic Steatohepatitis
Non-alcoholic Fatty Liver Disease

Clinical Trial Details

NCT number	NCT03294941
Study type	Interventional
Source	HepQuant, LLC
Contact
Status	Terminated
Phase	Phase 2
Start date	December 8, 2017
Completion date	September 11, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03289897` - Non-invasive Rapid Assessment of NAFLD Using Magnetic Resonance Imaging With LiverMultiScan	N/A
Active, not recruiting	`NCT05479721` - LITMUS Imaging Study
Not yet recruiting	`NCT05120557` - Point-of-care Ultrasound Screening and Assessment of Chronic Liver Diseases and NASH	N/A
Recruiting	`NCT04976283` - Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver	Phase 4
Completed	`NCT02784444` - A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH	Phase 2
Not yet recruiting	`NCT05499949` - The Franciscus Obesity NASH Study
Completed	`NCT04321343` - Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH)	Phase 2
Recruiting	`NCT04371042` - PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
Not yet recruiting	`NCT03648554` - Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)	Phase 4
Completed	`NCT04972396` - ALT-801 DDI Study in Healthy Volunteers	Phase 1
Completed	`NCT03748628` - Absorption, Metabolism and Excretion (AME) Study of [14C]EDP-305 in Healthy Male Subjects	Phase 1
Enrolling by invitation	`NCT05195944` - Semaglutide vs Sitagliptin	Phase 4
Completed	`NCT04643795` - Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects	Phase 1
Terminated	`NCT03669133` - Vitamin E for NASH Treatment in HIV Infected Individuals	Phase 2
Completed	`NCT04066400` - Role of a Wheat Containing Diet on Non-alcoholic Steatohepatitis	N/A
Completed	`NCT03536650` - Effect of DMR in the Treatment of NASH	N/A
Completed	`NCT03783897` - A Drug-drug Interaction Study to Investigate the Effect of Coadministration of EDP-305 on the PK of a Combined Oral Contraceptive in Healthy Female Subjects	Phase 1
Completed	`NCT04618744` - A Study to Assess the Safety and Efficacy of Oral Insulin in T2DM Patients With Nonalcoholic Steatohepatitis (NASH)	Phase 2
Active, not recruiting	`NCT05338034` - Phase 2a Study of HPG1860 in Subjects With NASH	Phase 2
Active, not recruiting	`NCT04653103` - NASH in Subjects With Different Classes of Obesity

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms